2-methylene-19-nor-20(S)-25-methyl-1a lpha-hydroxycalciferol and its uses

Details for Australian Patent Application No. 2004260642 (hide)

Owner Wisconsin Alumni Research Foundation

Inventors Grzywacz, Pawel K.; Deluca, Hector F.

Agent Pizzeys

Pub. Number AU-B-2004260642

PCT Pub. Number WO2005/011706

Priority 10/657,533 08.09.03 US; 10/613,201 03.07.03 US

Filing date 6 July 2004

Wipo publication date 10 February 2005

Acceptance publication date 22 April 2010

International Classifications

A61P 3/14 (2006.01) Drugs for disorders of the metabolism

A61K 31/59 (2006.01) - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems

A61P 17/06 (2006.01) Drugs for dermatological disorders

A61P 19/10 (2006.01) Drugs for skeletal disorders

A61P 35/00 (2006.01) Antineoplastic agents

A61P 35/02 (2006.01) Antineoplastic agents

Event Publications

12 January 2006 PCT application entered the National Phase

  PCT publication WO2005/011706 Priority application(s): WO2005/011706

22 April 2010 Application Accepted

  Published as AU-B-2004260642

19 August 2010 Standard Patent Sealed

2 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004260643-Particulate inorganic solids treated with organophosphinic compounds

2004260638-Methods of using adipose tissue-derived cells in augmenting autologous fat transfer